Studies showed that SCLC-N subtype is associated with MYC overexpression, and patients with SCLC-N may benefit from therapies such as CHK1 inhibitors (110), pegylated arginine deiminase (111) and Aurora A kinase inhibitors (112). Here, CHEK1 is linked to small cell lung carcinoma.